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ABSTRACT
The longer- term consequences of SARS- CoV-2 infection 
are uncertain. Consecutive patients hospitalised 
with COVID-19 were prospectively recruited to 
this observational study (n=163). At 8–12 weeks 
postadmission, survivors were invited to a systematic 
clinical follow- up. Of 131 participants, 110 attended the 
follow- up clinic. Most (74%) had persistent symptoms 
(notably breathlessness and excessive fatigue) and 
limitations in reported physical ability. However, clinically 
significant abnormalities in chest radiograph, exercise 
tests, blood tests and spirometry were less frequent 
(35%), especially in patients not requiring supplementary 
oxygen during their acute infection (7%). Results suggest 
that a holistic approach focusing on rehabilitation and 
general well- being is paramount.
INTRODUCTION
Limited studies exist on the longer- term outcomes 
of patients admitted to the hospital due to 
COVID-19. Although several guidelines have been 
published,1 2 these are based on extrapolation of 
complications from other coronavirus infections.3 4 
Disease- specific data on the outcomes for survivors 
of COVID-19 are essential to properly inform 
guidelines.
We report a prospectively recruited UK cohort 
of hospitalised patients with COVID-19. Consec-
utively hospitalised patients were recruited 
at diagnosis and followed- up at 8–12 weeks 
with a face- to- face medical review, spirometry, 
exercise test, blood tests, chest radiograph and 




Patients were recruited from the Diagnostic and 
Severity markers of COVID-19 to Enable Rapid 
triage (DISCOVER) study, a single- centre prospec-
tive study (Bristol, UK) recruiting consecutive 
patients (≥18 years of age) admitted with COVID-
19. Ethics approval was via South Yorkshire (REC: 
20/YH/0121). The inclusion criteria were a positive 
PCR result for SARS- CoV-2 or a clinico- radiological 
diagnosis of COVID-19 disease (see online supple-
mentary material).
Baseline assessment and 28-day follow-up
Baseline demographics, comorbidities and blood 
test results were extracted from the medical record. 
At 28 days, survivors were defined as having had 
severe disease (invasive mechanical ventilation, non- 
invasive ventilation and/or intensive care admis-
sion), moderate disease (supplementary oxygen 
during admission) or mild disease (no supplemen-
tary oxygen or intensive care).
Face-to-face outpatient follow-up
All patients who survived were offered follow- up at 
a respiratory outpatient clinic (except for nursing 
home residents or current hospital inpatients) 
8–12 weeks after their hospital admission. Those 
attending had a face- to- face review with a respira-
tory clinician, chest radiograph (CXR), spirom-
etry, exercise testing (using 1 min sit to stand test 
(STS)),5 routine blood tests, and SF-36 quality- 
of- life and Warwick- Edinburgh Mental Wellbeing 
Scales (WEMWBS) questionnaires. The severity 
and nature of abnormalities detected on CXR were 
scored and described (online supplementary mate-
rial for full details).6
RESULTS
Between 30 March and 3 June 2020, 163 partici-
pants with COVID-19 were recruited. Of these, 19 
patients died and 13 were inpatients from hospital/
nursing home. The remaining 131 were invited for 
follow- up and 110 attended. Eighteen declined: 
ongoing shielding (n=10), being care providers 
(n=3) and felt unnecessary (n=5). Three were 
uncontactable (see supplementary material: Consol-
idated Standards of Reporting Trials). Table 1 shows 
the baseline demographics and clinical outcomes of 
those who attended follow- up divided by severity 
of COVID-19 illness (median age 60 years (IQR 
46–73); 56% (n=91) male individuals). Patients 
were followed- up with a median of 83 days (IQR 
74–88 days) after hospital admission and 90 days 
(IQR 80–97 days) after COVID-19 symptom onset.
Symptoms
Although most symptoms were improving, 81 
(74%) patients reported at least one ongoing 
symptom: 39% breathlessness, 39% fatigue and 
24% insomnia (see figure 1). Sixteen (59%) 
patients in the mild COVID-19 group reported 
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ongoing symptoms compared with 49 (75%) and 16 (89%) in 
the moderate and severe group, respectively (figure 2).
Radiology
Of the 15/110 (14%) patients with abnormal follow- up radio-
graphs (n=10 moderate group, n=5 severe group), 2 had wors-
ened from hospital admission with higher radiographic severity 
scores (both had known previous interstitial lung disease). 
Findings seen included consolidation (one patient), reticulation 
(eight patients), atelectasis (five patients) and pleural effusion 
(one patient). High- resolution CT (HRCT) scans performed on 
the basis of the clinical, spirometric or radiological findings (nine 
patients) showed fibrotic changes in two patients with moderate 
disease at baseline (other HRCT results: normal (four), minor 
persistent ground glass changes (two), pleural effusion(one)).
Pulmonary function testing
Eleven patients had restrictive spirometry and 15 had a signif-
icant desaturation on the STS test, all within the severe or 
moderate group (see the online supplementary material).
Health-related quality of life
SF-36 scores demonstrated a reduction in reported health status 
across all domains compared with age- matched population 
norms.7 In particular, physical scores were significantly lower in 
the severe cohort compared with mild/moderate (see the online 
supplementary material). In contrast, WEMWBS scores were 
comparable with published population norms,8 with no signif-
icant difference between groups.
Blood results
Thirty- five (32%) patients had significantly deranged liver 
(n=12) or renal (n=9) function recorded during admission. 
All improved and 32 of 35 results had returned to base-
line. Two additional patients had an ongoing lymphopenia 
and two were with a C- reactive protein level greater than 
10 mg/L.
DISCUSSION
Over 130 000 people have been admitted to hospital with 
COVID-19 in the UK alone. As admission rates begin to fall, 
the potential impact of ‘post- COVID’ syndromes on patients 
and the health services is becoming apparent. We present a UK 
cohort study of consecutively recruited patients hospitalised 
with COVID-19 and systematically assessed after discharge. Our 
key finding is that nearly three- quarters of patients remain symp-
tomatic at 3 months, while clinical abnormalities were rare in 
mild disease.
Few studies have reported results from systematic prospec-
tive follow- up after hospitalisation. Our findings are in 
keeping with an Italian cohort of patients asked to recall their 
admission symptoms and HRQoL at a median of 60 days post-
discharge, finding that 87% had at least one ongoing symptom 
with fatigue (53%) and shortness of breath (43%) predom-
inating.9 Similar findings have been demonstrated in other 
follow- up studies.10
The British Thoracic Society (BTS) COVID-19 Guidance 
advises follow- up guidance depending on whether the patient 
required intensive/higher care versus ward/community care 
(equivalent to severe vs mild/moderate in this cohort).1 For mild/
moderate disease, BTS recommends virtual follow- up with a 
CXR. This study demonstrated a low likelihood of follow- up 
CXR abnormalities in patients not requiring oxygen for their 
acute infection, suggesting that this approach may not be 
necessary.
The wide range of symptoms and reduced HRQoL seen in 
this study re- enforces the importance of a holistic approach 
advocated by the BTS and other guidelines.1 2 All patients in our 
follow- up clinics were offered a referral to specialist psycholog-
ical support services.
We recognise potential limitations of this study including 
the single- centre design and relatively small patient numbers 
that may limit the generalisability of results. Second, patients 
residing in a nursing home or hospital inpatients were not 
followed- up in line with local infection control protocols.
The study demonstrates the persistence of symptoms at 
8–12 weeks in the majority of patients, even those admitted 
with mild disease. There was a reassuring improvement in 
clinical measures with only a minority having abnormal 
biochemical, radiological or spirometric tests. These results 
provide information useful to clinicians caring for survivors 
of COVID-19 disease. The role(s) of rehabilitation and/or 










Age (18+), years 47 (32–61) 57 (48–67) 62 (54–71)
BAME 5 (19%) 15 (23%) 3 (19%)
Male 13 (48%) 44 (68%) 11 (61%)
BMI (mean) 31.2 32.5 32.5
Comorbidities
T1DM 1 (3.7%) 1 (1.5%) 1 (5.6%)
T2DM 2 (7.4%) 12 (18%) 2 (11%)
Heart disease 6 (22%) 11 (17%) 3 (17%)
Chronic lung disease 4 (15%) 16 (25%) 8 (44%)
Severe liver disease 0 (0%) 1 (1.5%) 0 (0%)
Severe kidney disease 1 (3.7%) 4 (6.2%) 2 (11%)
Hypertension 4 (15%) 16 (25%) 7 (39%)




21 (78%) 50 (77%) 10 (56%)
SARS- CoV-2 IgG+ve (Abbott/
Roche)
(at follow- up)
18 (67%) 56 (86%) 15 (83%)
SARS- CoV-2 PCR–ve
(as inpatient) and SARS- CoV-2 
IgG–ve (at follow- up)
3 (11%) 6 (9%) 2 (11%)
Outcomes
Admission NEWS score (IQR) 2 (1–3) 4 (2–6) 5 (4–8)
Radiographic severity score on 
admission chest radiograph
0 (0–2) 3 (1.75–4) 3 (1.25–6)
Invasive or non- invasive 
ventilation required
0 (0%) 0 (0%) 16 (89%)
Supplementary oxygen required 0 (0%) 65 (100%) 18 (100%)
Hospital length of stay, days 2 (1–4) 5 (2–8) 10 (7–17)
BAME, Black, Asian and minority ethnic; BMI, body mass index; NEWS, National 
Early Warning Score; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes 
mellitus.
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psychological services in the management of such patients 
warrant research.
Twitter Fergus W Hamilton @gushamilton, Catherine Hyams @cathyams and James 
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